Related Experiment Video
Updated: Dec 20, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
[Tumor vaccines-therapeutic vaccination against cancer]
H-G Rammensee1,2,3, M W Löffler4,5,6,7,8, J S Walz4,5,6,9,10
1Interfakultäres Institut für Zellbiologie (IFIZ), Abteilung Immunologie, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Deutschland. rammensee@uni-tuebingen.de.
Abstract:
Tumor cells always exhibit differences to normal cells. These differences can be recognized by the immune system, enabling the destruction of tumor cells by T cells, as was impressively demonstrated by the success of immune checkpoint inhibition, e.g., in malignant melanoma. Many cancers, however, do not respond to this kind of therapy. In these cases, vaccination against tumor antigens could be very helpful. Nevertheless, all of the efforts made in this respect during the past 30 years have been virtually futile. With current knowledge and technology there is new hope.
Insights
Cancer cells differ from normal cells, allowing T-cells to target them. While immune checkpoint inhibitors work for some cancers, new approaches like tumor antigen vaccination offer hope for hard-to-treat and unresponsive cancers.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Tumor cells possess unique antigens recognizable by the immune system.
- Immune checkpoint inhibition has shown success in treating certain cancers, like melanoma.
- Many cancers remain unresponsive to current immunotherapies, necessitating alternative strategies.
Purpose of the Study:
- To explore the potential of tumor antigen vaccination as a therapeutic strategy for cancers unresponsive to existing treatments.
- To highlight the challenges and recent advancements in cancer vaccine development.
Main Methods:
- Review of existing research on tumor immunology and cancer vaccines.
- Analysis of the limitations of previous vaccination efforts.
- Discussion of current technological advancements relevant to vaccine development.
Main Results:
- Despite decades of research, cancer vaccination has yielded limited success.
- Tumor cell-specific antigens present a viable target for immune-mediated destruction.
- Recent progress in immunology and technology offers renewed hope for effective cancer vaccines.
Conclusions:
- Cancer vaccination remains a promising but challenging field.
- Overcoming past failures requires leveraging new knowledge and technological innovations.
- Future research should focus on developing effective tumor antigen vaccines for a broader range of cancers.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...